)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Chordate Medical
Chordate Medical (CMH) investor relations material
Chordate Medical has been delisted
Chordate Medical Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary29 Aug, 2025
Executive summary
Revenue for January–June 2025 increased 76% year-over-year to 759,260 SEK, with 61% from EU and 39% from MEA markets.
Net loss after tax for the half-year was -10,948,833 SEK, an improvement from -13,042,462 SEK year-over-year.
Significant cost reduction measures underway, targeting a 60% decrease in operating expenses from September 2025.
Focus remains on the exit process, aiming to sell the business to a larger medtech or pharma company.
Financial highlights
Q2 2025 net sales were 163,155 SEK, down from 172,941 SEK in Q2 2024.
Cash flow from operations for H1 2025 was -13,187,108 SEK, compared to -12,907,262 SEK in H1 2024.
Cash and bank balances at June 30, 2025, stood at 4,243,740 SEK, down from 11,512,033 SEK a year earlier.
Result per share for H1 2025 was -3.45 SEK (adjusted for reverse split), compared to -15.96 SEK in H1 2024.
Outlook and guidance
Ongoing exit process with several interested parties; focus on achieving a sale in the near term.
Further cost reductions expected to maintain customer service and regulatory status while supporting the exit process.
Additional financing may be required if the sale is not completed as planned.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Chordate Medical
- Losses narrowed as Chordate advanced exit plans and gained Saudi approval for Ozilia® Migraine.CMH
Q3 2024 - Losses narrowed and international expansion advanced with new Swiss market entry.CMHQ2 2024
- Sales surged 131% and SEK 17.7M was raised to fund Chordate's strategic exit and growth.CMHQ1 2025
- Ozilia® migraine treatment gained traction in new markets as Chordate pursued an exit strategy.CMHQ4 2024
Chordate Medical
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Chordate Medical Holding AB is a medical technology company that has developed and patented Ozilia Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The company focuses on providing solutions for patients suffering from chronic nasal congestion and chronic migraine, aiming to offer effective and non-pharmacological treatment options. The company is headquartered in Sweden, and its shares are listed on the Stockholm Stock Exchange.